LONDON – Geneuro SA announced positive results from the Phase IIa trial of GNbAC1, a first-in-class monoclonal antibody targeting an endogenous retroviral protein identified as involved in the onset and development of multiple sclerosis (MS), with the drug showing a very good safety profile and nine of 10 patients having stable disease, as assessed by MRI brain scans.